Bryce Point Capital LLC Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Bryce Point Capital LLC purchased a new stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,522 shares of the biotechnology company's stock, valued at approximately $1,243,000.

A number of other hedge funds have also bought and sold shares of UTHR. Signaturefd LLC grew its position in United Therapeutics by 4.7% during the fourth quarter. Signaturefd LLC now owns 663 shares of the biotechnology company's stock worth $234,000 after buying an additional 30 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of United Therapeutics by 2.8% during the 4th quarter. Parallel Advisors LLC now owns 1,090 shares of the biotechnology company's stock worth $385,000 after purchasing an additional 30 shares in the last quarter. Great Lakes Advisors LLC increased its position in shares of United Therapeutics by 1.6% in the fourth quarter. Great Lakes Advisors LLC now owns 1,974 shares of the biotechnology company's stock worth $697,000 after purchasing an additional 31 shares during the period. Oregon Public Employees Retirement Fund increased its position in shares of United Therapeutics by 0.4% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 9,108 shares of the biotechnology company's stock worth $3,214,000 after purchasing an additional 33 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its stake in United Therapeutics by 0.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company's stock valued at $1,761,000 after purchasing an additional 39 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Remove Ads

United Therapeutics Trading Down 0.9 %

UTHR traded down $2.51 during trading on Tuesday, reaching $289.22. 86,194 shares of the company's stock were exchanged, compared to its average volume of 449,898. United Therapeutics Co. has a one year low of $230.39 and a one year high of $417.82. The firm has a fifty day moving average price of $332.23 and a two-hundred day moving average price of $354.12. The stock has a market capitalization of $12.99 billion, a PE ratio of 12.70, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same quarter in the previous year, the business earned $4.36 earnings per share. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insiders Place Their Bets

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $11,261,606.58. This represents a 23.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $364.62, for a total transaction of $3,646,200.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $939,625.74. This represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 83,500 shares of company stock worth $29,502,480. 11.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on UTHR shares. UBS Group raised their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a "buy" rating in a report on Wednesday, January 8th. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.